NP方案治疗晚期非小细胞肺癌的疗效观察  

Clinical effect of NP regimen in advanced non-small cell lung cancer

作　　者：陈素琼[1] 师卫华[1] 袁葆琳[1] 梁海田[1] 

机构地区：[1]宁夏医学院第二附属医院肿瘤内科,宁夏银川750001

出　　处：《现代肿瘤医学》2006年第10期1225-1226,共2页Journal of Modern Oncology

摘　　要：目的：评价NP方案（长春瑞宾＋顺铂）对晚期非小细胞肺癌的疗效和毒副作用。方法：64例经病理或细胞学诊断为非小细胞肺癌患者，初治46例，复治18例。以NP方案化疗，每例2～6周期，共168个周期。结果：总有效率43．8％。稳定（SD）37．5％。进展（PD）18．7％。中位进展期（TTP）6个月，中位生存期13个月，一年生存率53．1％。毒副反应主要为Ⅲ、Ⅳ度白细胞下降（39．0％）。结论：NP方案治疗晚期非小细胞肺癌有较好的疗效，毒副反应可耐受，价格适中，符合我国的国情。Objective：To observe the efficacy and toxicity of NP regimen （navelbine plus cisplatin ）in the treatment of advanced non- small cell lung can cer（NSCLC） . Methods： Sixty four patients with advanced NSCLC were comfirmed by pathology or cytology entered in to stady among them . 46 patients had no prior chemotherapy and 18 received previous chemotherapy. They were all treated by navelbine plus cisplatin with 168 cycles. Results： The response rate （CR ＋ PR） was 43.8% ,SD 24（37.5% ）, PD 12（ 18.7% ）. Median time of progression（TIP） was 6 months, median survival time was 13 months . One - year survival rate was 53.1%. The dose limiting toxicity was neutropenia that developed in 82.8% of the patients（39.0% with grades Ⅲ and Ⅳ）. Conclusion： The results suggested that the NP regimen for advanced NSCLC is effective and the toxicties axe tolerable.

关 键 词：非小细胞肺癌 化疗 长春瑞宾 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]